All news

FDA flags rare eye condition risk with GLP-1 drugs

CNBC · RSS · · AI-summarised by FinFlash

The FDA has found evidence of a potential increased risk of a rare eye condition tied to GLP-1 drugs used for weight management and diabetes, including Wegovy and Zepbound. The agency's warning covers a class of medicines that has driven major revenue growth for Novo Nordisk and Eli Lilly.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.